Literature DB >> 11413308

Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy.

A J Hance1, V Lemiale, J Izopet, D Lecossier, V Joly, P Massip, F Mammano, D Descamps, F Brun-Vézinet, F Clavel.   

Abstract

Mutations in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and protease that confer resistance to antiretroviral agents are usually accompanied by a reduction in the viral replicative capacity under drug-free conditions. Consequently, when antiretroviral treatment is interrupted in HIV-1-infected patients harboring drug-resistant virus, resistant quasi-species appear to be most often replaced within several weeks by wild-type virus. Using a real-time PCR-based technique for the selective quantification of resistant viral sequences in plasma, we have studied the kinetics of the switch from mutant to wild-type virus and evaluated the extent to which minority populations of resistant viruses not detected by genotyping persist in these individuals. Among 12 patients with viruses expressing the V82A or L90M resistance mutation who had undergone a 3-month interruption of therapy and for whom conventional genotyping had revealed an apparent total reconversion to wild-type virus, minority populations expressing these mutations, representing 0.1 to 21% of total virus, were still detectable in 9 cases. Kinetic studies demonstrated that viruses expressing resistance mutations could be detected for >5 months after the discontinuation of treatment in some patients. Most of the minority resistant genomes detected more than 3 months after the interruption of therapy carried only part of the mutations present in the resistant viruses prior to treatment interruption and appeared to result from the emergence of existing strains selected at earlier stages in the development of drug resistance. Thus, following the interruption of treatment, viral populations containing resistance mutations can persist for several months after the time when conventional genotyping techniques detect only wild-type virus. These populations include viral strains with only some of the resistance mutations initially present, strains that presumably express better fitness under drug-free conditions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11413308      PMCID: PMC114364          DOI: 10.1128/JVI.75.14.6410-6417.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  32 in total

1.  HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group.

Authors:  A U Neumann; R Tubiana; V Calvez; C Robert; T S Li; H Agut; B Autran; C Katlama
Journal:  AIDS       Date:  1999-04-16       Impact factor: 4.177

2.  Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype.

Authors:  C Verhofstede; F V Wanzeele; B Van Der Gucht; N De Cabooter; J Plum
Journal:  AIDS       Date:  1999-12-24       Impact factor: 4.177

Review 3.  The year in review: antiretroviral treatment.

Authors:  B Hirschel; M Opravil
Journal:  AIDS       Date:  1999       Impact factor: 4.177

Review 4.  RNA virus mutations and fitness for survival.

Authors:  E Domingo; J J Holland
Journal:  Annu Rev Microbiol       Date:  1997       Impact factor: 15.500

5.  Reduction in human immunodeficiency virus type 1 mutations associated with drug resistance after initiating new therapeutic regimens in pretreated patients.

Authors:  H L Devereux; C Loveday; M Youle; C A Sabin; A Burke; M A Johnson
Journal:  J Infect Dis       Date:  2000-05-15       Impact factor: 5.226

6.  Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples.

Authors:  H F Günthard; J K Wong; C C Ignacio; D V Havlir; D D Richman
Journal:  AIDS Res Hum Retroviruses       Date:  1998-07-01       Impact factor: 2.205

7.  Minimizing DNA recombination during long RT-PCR.

Authors:  G Fang; G Zhu; H Burger; J S Keithly; B Weiser
Journal:  J Virol Methods       Date:  1998-12       Impact factor: 2.014

8.  Stimulation and suppression of PCR-mediated recombination.

Authors:  M S Judo; A B Wedel; C Wilson
Journal:  Nucleic Acids Res       Date:  1998-04-01       Impact factor: 16.971

9.  Oligomerization within virions and subcellular localization of human immunodeficiency virus type 1 integrase.

Authors:  C Petit; O Schwartz; F Mammano
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

10.  Resistance profiles in patients with viral rebound on potent antiretroviral therapy.

Authors:  A Cozzi Lepri; C A Sabin; S Staszewski; K Hertogs; A Müller; H Rabenau; A N Phillips; V Miller
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

View more
  34 in total

1.  Colinearity of reverse transcriptase inhibitor resistance mutations detected by population-based sequencing.

Authors:  Matthew J Gonzales; Elizabeth Johnson; Kathryn M Dupnik; Tomozumi Imamichi; Robert W Shafer
Journal:  J Acquir Immune Defic Syndr       Date:  2003-12-01       Impact factor: 3.731

2.  Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID.

Authors:  Cassandra B Jabara; Corbin D Jones; Jeffrey Roach; Jeffrey A Anderson; Ronald Swanstrom
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-30       Impact factor: 11.205

3.  In vivo patterns of resistance to the HIV attachment inhibitor BMS-488043.

Authors:  Nannan Zhou; Beata Nowicka-Sans; Sharon Zhang; Li Fan; Jie Fang; Hua Fang; Yi-Fei Gong; Betsy Eggers; David R Langley; Tao Wang; John Kadow; Dennis Grasela; George J Hanna; Louis Alexander; Richard Colonno; Mark Krystal; Pin-Fang Lin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

Review 4.  Minority variants of drug-resistant HIV.

Authors:  Sara Gianella; Douglas D Richman
Journal:  J Infect Dis       Date:  2010-09-01       Impact factor: 5.226

5.  Use of a locked-nucleic-acid oligomer in the clamped-probe assay for detection of a minority Pfcrt K76T mutant population of Plasmodium falciparum.

Authors:  Alice Senescau; Antoine Berry; Françoise Benoit-Vical; Olfert Landt; Richard Fabre; Joël Lelièvre; Sophie Cassaing; Jean-François Magnaval
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

6.  Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency.

Authors:  Elias K Halvas; Grace M Aldrovandi; Peter Balfe; Ingrid A Beck; Valerie F Boltz; John M Coffin; Lisa M Frenkel; J Darren Hazelwood; Victoria A Johnson; Mary Kearney; Andrea Kovacs; Daniel R Kuritzkes; Karin J Metzner; Dwight V Nissley; Marek Nowicki; Sarah Palmer; Rainer Ziermann; Richard Y Zhao; Cheryl L Jennings; James Bremer; Don Brambilla; John W Mellors
Journal:  J Clin Microbiol       Date:  2006-07       Impact factor: 5.948

7.  Evolution of drug-resistant viral populations during interruption of antiretroviral therapy.

Authors:  Dongning Wang; Charles B Hicks; Neela D Goswami; Emi Tafoya; Ruy M Ribeiro; Fangping Cai; Alan S Perelson; Feng Gao
Journal:  J Virol       Date:  2011-04-13       Impact factor: 5.103

8.  Female genital tract shedding of CXCR4-tropic HIV Type 1 is associated with a majority population of CXCR4-tropic HIV Type 1 in blood and declining CD4(+) cell counts.

Authors:  Richard E Haaland; Sharon T Sullivan; Tammy Evans-Strickfaden; Jeffrey L Lennox; Clyde E Hart
Journal:  AIDS Res Hum Retroviruses       Date:  2012-03-23       Impact factor: 2.205

9.  Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer design.

Authors:  Valerie F Boltz; Frank Maldarelli; Neil Martinson; Lynn Morris; James A McIntyre; Glenda Gray; Mark J Hopley; Toshio Kimura; Douglas L Mayers; Patrick Robinson; John W Mellors; John M Coffin; Sarah E Palmer
Journal:  J Virol Methods       Date:  2009-12-03       Impact factor: 2.014

10.  Replication and drug resistant mutation of HIV-1 subtype B' (Thailand B) variants isolated from HAART treatment individuals in China.

Authors:  Jianping Sun; Liying Ma; Xiaoling Yu; Yang Huang; Lin Yuan; Yiming Shao
Journal:  Virol J       Date:  2009-11-18       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.